Pfizer Appoints Head of Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Appoints Head of Vaccines



Pfizer has named Albert Bourla as group president of the company’s Vaccines, Oncology and Consumer Healthcare business and Susan Silbermann as president and general manager, Global Vaccines business, both effective Jan. 1, 2014.
 
Doug Lankler, who was to become general counsel on January 1, and Rady Johnson who was to become chief compliance and risk officer on January 1, both assume their new positions immediately. 

On January 1, the company will begin operating with three commercial businesses-the Global Innovative Pharmaceutical business, led by Geno Germano, the Global Established Pharmaceutical business, led by John Young, and the Vaccines, Oncology, and Consumer Healthcare business led by Albert Bourla.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here